Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Organon reported $1.59 billion in revenue for Q2 2025, reflecting a year-over-year decline of 0.8% and an EPS of $1.00, down from $1.12 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $1.55 billion by 2.63%, while the EPS surpassed the consensus estimate of $0.94 by 6.38% [1] Revenue Performance by Segment - Established Brands in the U.S. for Respiratory (Singulair) generated $2 million, slightly above the $1.95 million estimate, with no year-over-year change [4] - Women's Health International for Nexplanon/Implanon NXT achieved $77 million, exceeding the $75.7 million estimate, marking a 10% increase year-over-year [4] - Women's Health U.S. for NuvaRing reported $7 million, matching estimates but showing a 30% decline year-over-year [4] - Women's Health International for Follistim AQ reached $43 million, surpassing the $41.53 million estimate, reflecting a 7.5% increase year-over-year [4] - Women's Health for Nexplanon/Implanon NXT totaled $240 million, below the $258.98 million estimate, with a slight decline of 0.8% year-over-year [4] - Women's Health for Follistim AQ generated $74 million, exceeding the $69.57 million estimate, showing a 19.4% increase year-over-year [4] - Total revenue for Established Brands was $936 million, above the $905.64 million estimate, but down 2.8% year-over-year [4] - Biosimilars total revenue reached $173 million, exceeding the $153.98 million estimate, with a year-over-year increase of 5.5% [4] - Total revenue for Women's Health was $462 million, slightly below the $471.79 million estimate, with a year-over-year increase of 2.9% [4] - Other revenue totaled $23 million, above the $21.74 million estimate, but down 25.8% year-over-year [4] - Women's Health for NuvaRing reported $28 million, exceeding the $22.99 million estimate, with a 3.5% decline year-over-year [4] - Biosimilars for Renflexis generated $63 million, surpassing the $56.8 million estimate, but reflecting an 8.7% decline year-over-year [4] Stock Performance - Organon's shares returned -0.5% over the past month, compared to a +1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]